// App-Quantinova.ai

2612 : Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.

Researchers

Presenter

  • Elena Geuna

Principal Investigators

  • Desamparados Roda

  • Karim Rihawi

  • Timothy Anthony Yap

  • Stanley B. Kaye

  • Johann Sebastian De Bono

  • L Rhoda Molife

  • Udai Banerji

  • Saeed Rafii

  • Begona Jimenez

  • Marta Capelan

Medical Centers

  • Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom

  • Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United KingdomThe Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United KingdomThe Royal Marsden NHS Foundation Trust, Surrey, United Kingdom

  • Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hyperglycemia

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved